Quarterly Result30 May 2026, 11:01 pm
Panacea Biotec: Rajinder Singh Manku Appointed as Director
AI Summary
Panacea Biotec Ltd's Board of Directors approved the appointment of Mr. Rajinder Singh Manku as an additional non-executive independent director, effective July 1, 2026, for a 5-year term, subject to shareholder approval. The board also approved the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, with an unmodified auditor's opinion. The company passed over dividend payments for FY26 due to losses. Total income from operations for the year ended March 31, 2026, was ₹41,349 Lakh, with a net loss of ₹2,988 Lakh after tax.
Key Highlights
- Rajinder Singh Manku appointed as additional non-executive independent director effective July 1, 2026.
- Standalone and consolidated audited financial results for FY26 approved with unmodified auditor's opinion.
- No dividend declared for FY26 due to losses incurred during the year.
- Total income from operations for FY26 was ₹41,349 Lakh.
- Net loss after tax for FY26 was ₹2,988 Lakh.
Price Impact
More from PANACEABIO